XBiotech Says The Primary Endpoint For The Phase 2 Study Was To Assess The Safety And Tolerability Of Natrunix When Used With The ON+5FU+LV Combination, There Were Fewer Adverse Events Of Any Kind During The 24-Week Treatment Period For The Natrunix...
XBiotech Says The Primary Endpoint For The Phase 2 Study Was To Assess The Safety And Tolerability Of Natrunix When Used With The ON+5FU+LV Combination, There Were Fewer Adverse Events Of Any Kind During The 24-Week Treatment Period For The Natrunix...
Xbiotech表示，第2期研究的主要終點是評估當Natrunix與ON+5FU+LV組合使用時的安全性和耐受性，在24周的治療期間，Natrunix的任何種類的不良事件更少。
XBiotech Says The Primary Endpoint For The Phase 2 Study Was To Assess The Safety And Tolerability Of Natrunix When Used With The ON+5FU+LV Combination, There Were Fewer Adverse Events Of Any Kind During The 24-Week Treatment Period For The Natrunix Arm Compared To Placebo, With Markedly Fewer Events In Specific Categories Of Adverse Events During That Time
Xbiotech表示，該2期研究的主要終點是評估Natrunix與ON+5FU+LV聯合使用時的安全性和耐受性，在24周治療期內，Natrunix組的任何類型的不良事件都比安慰劑組少，特定的不良事件類別在該期間發生的事件明顯更少。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間